Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 584

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 584
---
 upon consolidation.

Use
of estimates

The
preparation of financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the
reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value
of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates
its estimates and assumptions on an ongoing basis using historical experience and other factors and makes adjustments when facts and
circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore,
actual results could differ from those estimates.

Loss
per share

Loss
per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of shares
of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of shares of common stock
and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which
are included under the treasury stock method when dilutive.

The
following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would
have been anti-dilutive for the periods presented (share data):

SCHEDULE
OF ANTI-DILUTIVE SECURITIES 

    Weighted average 

    For the year ended December 31, 

    2024  
    2023 
  
    Outstanding stock options 
     2,519,419  
     1,979,196 
  
    Warrants 
     3,935,282  
     3,090,787 

Cash
and cash equivalents

The
Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of
December 31, 2024, and 2023, cash and cash equivalents consist primarily of checking and money market deposits. The Company’s cash
balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the
financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized
any losses caused by uninsured balances.

Property
and equipment

Property
and equipment assets are stated at cost less accumulated depreciation. Depreciation is